-
Ascent Pharma's MDM2 inhibitor APG-115 combined with pembrolizumab has good prospects for the treatment of solid tumor patients resistant to immuno-oncology drugs
Time of Update: 2021-07-06
Among them, the Phase II clinical study of APG-115 combined with pembrolizumab in patients with unresectable/metastatic melanoma or advanced solid tumors who have failed immuno-oncology drug therapy has shown good prospects .
-
"Tumor treatment shady" punishment result is here!
Time of Update: 2021-07-06
On May 28, the official website of the Supervision Office of the Shanghai Municipal Health Commission announced the relevant punishment results of Lu Wei, the doctor involved in the "tumor treatment shady" .
-
Tianyao Co., Ltd.: Subsidiary medicines have been approved by the US ANDA
Time of Update: 2021-07-06
On June 16, Tianyao Pharmaceutical announced that Jinyao Pharmaceutical, a subsidiary of the company, recently obtained the approval number of the new drug brief application (ANDA, US generic drug ap
-
Lifetech's Xuper Aortic Stent Graft System Obtained EU CE Certification
Time of Update: 2021-07-06
Compared with traditional surgery, hybrid surgery has the advantages of shorter operating cycle and relatively less trauma to patients, and has become the mainstream surgical method for the treatment of Stanford A-type aortic dissection .
-
Medtronic-Kanghui dual brand debut at CAOS
Time of Update: 2021-07-06
Medtronic and Kanghui Orthopedics joined forces to make their debut in a dual-brand form, bringing nearly 20 innovative products including the integration of spine, trauma and smart surgery to the conference .
-
Deqi Pharmaceuticals Shaoxing production base is completed to accelerate the launch of innovative drugs in China
Time of Update: 2021-07-06
The completion of the base has laid a solid foundation for the commercial production of Deqi Pharmaceutical solid preparation products, marking that Deqi Pharmaceutical has moved towards an innovative pharmaceutical company in the entire industry chain integrating early R&D, clinical research, production and commercialization .
-
Beike Biotech IPO plans to publicly issue 41,284,070 shares, preliminary inquiry on June 9
Time of Update: 2021-07-06
to produce 20 million copies of live attenuated varicella vaccine and herpes zoster vaccine; 294 million yuan will be used in Changchun Baike Biotechnology Co.
produces 6 million copies of acellular DPT (three-component) joint vaccine project; 163 million yuan is used for Changchun Baike Biotechnology Co.
-
Numab Therapeutics, an investment company of Sansheng Guojian, completes Series C financing
Time of Update: 2021-07-06
Prior to this, the two parties reached an agreement that Sansheng Guojian will develop and commercialize a series of new multispecific antibodies for cancer treatment based on Numab's technology platform .
-
Nuocheng Jianhua will announce the clinical data of the pan-FGFR inhibitor gunagratinib at the annual meeting of the American Society of Clinical Oncology in 2021
Time of Update: 2021-07-06
Biomedical high-tech company Nuocheng Jianhua (Hong Kong Stock Exchange code: 09969) today announced that the company's pan-FGFR inhibitor gunagratinib (ICP-192) clinical data will be announced at the 2021 American Society of Clinical Oncology (ASCO) annual meeting , And was selected to be displayed in the form of a poster.
-
Tuoyi urothelial cancer indications national launch meeting in Chengdu ended
Time of Update: 2021-07-06
Thousands of urology experts from across the country gather to launch Tuoyi® (Treprizumab) Urothelial Cancer Indications As an opportunity, we will jointly discuss the current status and progress of diagnosis and treatment of urothelial cancer, and look forward to more breakthroughs in the immunotherapy of epithelial cancer and the treatment of urinary tumors in China .
-
Milestone Pharmaceuticals announces an exclusive license agreement with Jixing Pharmaceuticals
Time of Update: 2021-07-06
The company today announced that it has reached an exclusive license and cooperation agreement with Jixing Pharmaceutical ("Jixing") to develop in Greater China for patients with paroxysmal supraventricular tachycardia (PSVT) and other cardiovascular diseases The experimental drug Etripamil, and its commercialization will be realized after approval .
-
Bayer and Alibaba Health launch in-depth cooperation to realize the digital drug management of patients throughout the course of the disease
Time of Update: 2021-07-06
" In addition, relying on the ecological layout, self-operated links and warehousing system in the Alibaba health field, the two parties will also cooperate in Internet hospital projects and new drug retail business to jointly explore new online prescription circulation models in order to realize the line of chronic disease patients.
-
Genting Xinyao's innovative drug for the treatment of metastatic triple-negative breast cancer, gosartuzumab, was included in the priority review category by the National Medical Products Administration
Time of Update: 2021-07-06
Gosartuzumab is used to treat adult patients with locally unresectable advanced or metastatic triple-negative breast cancer (at least one of which is metastatic disease) who has received at least two lines or more of previous treatment .
-
Astellas releases 5-year strategic plan, 2026 performance is expected to reach 16.5 billion US dollars
Time of Update: 2021-07-06
Soon after, the British Medicines and Health Products Administration (MHRA) approved Xtandi for the treatment of adult male patients with metastatic hormone-sensitive prostate cancer (mHSPC) .
-
Roche's Class 1 Innovative Drug Lisporan Oral Solution Powder Approved for Marketing
Time of Update: 2021-07-06
This product is a drug for the treatment of rare diseases in children, and the indication is Spinal muscular atrophy (SMA) in patients 2 months of age and older .
-
Chuangsheng Group announced that it will announce the phase I updated clinical data of its pH-dependent PD-L1 antibody MSB2311 at the ASCO conference in 2021
Time of Update: 2021-07-06
Update on the safety and efficacy data of the Phase I clinical study of pH-dependent PD-L1 antibody MSB2311 in patients with advanced solid tumors and hematological malignancies in China Abstract Number: e14547 First author: Shen Lin, Doctor of Medicine (Peking University Cancer Hospital) About MSB2311: MSB2311 is a humanized antibody that binds to PD-L1 in a pH-dependent manner .
-
Winbond Health Methylprednisolone Sodium Succinate for Injection passed the consistency evaluation of generic drugs
Time of Update: 2021-07-06
On June 9th, Winbond Health announced that Winbond Pharmaceuticals, a wholly-owned subsidiary, has recently received the "Notice of Supplementary Application Approval" for methylprednisolone sodium succinate for chemical injections approved and issued by the National Medical Products Administration.
-
Zhenbaodao intends to enter the field of biopharmaceuticals with a 16.67% stake in Terris for 400 million
Time of Update: 2021-07-06
On the evening of June 15th, Zhenbaodao issued an announcement stating that it had signed an investment cooperation agreement with Zhejiang Teruisi Pharmaceutical Co.
Among them, Treasure Island invested 400 million yuan, accounting for 16.
It has 11 innovative drugs and biosimilar products under development.
-
Zhifei Biological and Human Welfare Pharmaceutical Innovative Drugs Enter the Administrative Approval Stage
Time of Update: 2021-07-06
Being able to enter the administrative approval stage means that the conclusion of the technical review is "approved.
-
The 10 billion complement inhibitor market "triples", Alexion's exclusive position was broken; Novartis, Sanofi...
Time of Update: 2021-07-06
A variety of research varieties are already on the way Novartis, Sanofi and others enter the game In addition to the three approved complement inhibitor drugs, there are currently many drugs under development, such as Sanofi’s sutimlimab, Novartis’s iptacopan (LNP023), Vifor Pharmaceuticals/ChemoCentryx’s avacopan (CCX168), Akari’s nomacopan, Achillion's danicopan, Annexon company ANX005, Ra's zilucoplan and so on .
